1. What conditions has MCT Oil been studied for?

• Very preterm infant outcomes (neonatal respiratory morbidity/BPD-related outcomes): In a randomized double-blind trial (ImNuT), MCT oil was used as the control supplement against ARA+DHA in infants <29 weeks’ gestation, with outcomes including days of respiratory support and bronchopulmonary dysplasia (BPD)-related measures.

• Drug-resistant epilepsy (ketogenic diet therapy): The medium-chain triglyceride ketogenic diet (MCTKD) uses MCT oil to generate ketones and is discussed as an effective dietary therapy for intractable epilepsy, particularly in children.

• Cognitive decline / mild cognitive impairment / Alzheimer’s disease (AD): A systematic review/meta-analysis evaluated medium-chain fatty acid (MCFA) supplements (often delivered as MCTs) for effects on circulating ketones and cognition in subjective cognitive decline, MCI, and AD.

• Airway inflammation (preclinical model): In guinea pigs with LPS-induced pulmonary inflammation, MCT oil was used as a vehicle/solvent for oral cannabinoid formulations (CBD/CBG), compared with a surfactant-based micellar formulation (Cremophor EL).

• Nutrient/bioactive delivery and digestion (food/nutraceutical formulation research): Multiple studies examine MCT oil in emulsions/oleogels to deliver compounds such as curcumin, resveratrol, and β-carotene, including stability through simulated digestion and bioaccessibility/permeation.

• Food processing applications (not a medical condition): MCT (or oils including MCT) are studied for effects on texture/processing in high-moisture extrusion and emulsion structure.

2. Does it work in treating those conditions? Summarize the evidence.

• Preterm infant respiratory outcomes: The trial cited did not test MCT oil as an active treatment; it used MCT oil as the control. The intervention (ARA 100 mg/kg + DHA 50 mg/kg daily) reduced days of respiratory support versus MCT control (mean 63.4 vs 80.6 days; p=0.03). This supports benefit of ARA+DHA, but does not establish MCT oil efficacy for respiratory outcomes.

• Drug-resistant epilepsy (MCT ketogenic diet): The epilepsy abstract states the efficacy of MCTKD is “as excellent as” classic ketogenic diet and is supported by retrospective, prospective, and randomized studies (details not provided in the study). This suggests MCT oil can be an effective component of ketogenic therapy for seizure control, but the study does not quantify seizure reduction or provide specific trial results.

• Cognition in MCI/AD: The systematic review/meta-analysis reports that studies measuring blood ketones (n=12) found a significant increase in circulating ketone bodies with MCFA supplementation. However, cognitive outcomes were mixed, ranging from no improvement (n=4 studies) to improvement in others (exact effect sizes not shown in the study). Overall: consistent metabolic effect (ketosis), inconsistent clinical cognitive benefit.

• Airway inflammation (CBD/CBG study): When CBD/CBG were formulated in MCT oil, they showed no significant reduction in LPS-induced neutrophilia versus vehicle. In contrast, the same cannabinoids in a Cremophor EL micellar formulation reduced neutrophil recruitment by ~50–65% at highest doses. This suggests MCT oil may be a suboptimal vehicle for achieving anti-inflammatory efficacy of these cannabinoids in that model (likely due to lower solubility/absorption), but it does not mean MCT oil itself worsens inflammation.

• Bioactive delivery (curcumin/resveratrol/β-carotene): In vitro digestion and ex vivo permeation studies suggest that structuring MCT into an emulsion-templated oleogel can improve bioaccessibility (reported up to 1.13-fold for curcumin and 1.2-fold for resveratrol vs MCT oil control) and increase permeation (about 1.83x for curcumin and 1.13x for resveratrol). For β-carotene, stability/bioaccessibility depended on emulsifier and interfacial properties; β-carotene in protein-coated MCT droplets was more stable than in Tween-80-coated MCT systems. These are formulation findings, not direct evidence of disease treatment.

3. What health benefits does it have?

• Raises ketone bodies (alternative energy substrate): The cognition systematic review/meta-analysis found that MCFA supplementation consistently increased blood ketone bodies in all studies assessing ketones (n=12). This supports MCT/MCFA use for inducing nutritional ketosis, which may be relevant where brain glucose utilization is impaired (as hypothesized in preclinical AD).

• Supports ketogenic diet flexibility in epilepsy care: The MCT ketogenic diet allows more carbohydrate and protein than classic ketogenic diet because MCT oil is described as “more ketogenic than long-chain triglycerides,” potentially improving palatability and adherence (important practical benefit in pediatric epilepsy management).

• Potential to improve delivery of lipophilic nutraceuticals (formulation-dependent): MCT-based emulsions/oleogels can protect sensitive bioactives during simulated digestion and may enhance intestinal delivery (e.g., increased bioaccessible fraction and ex vivo permeation for curcumin/resveratrol in an emulsion-templated MCT oleogel vs MCT oil control).

• Food technology functionality (indirect consumer benefit): MCT oil can be incorporated into emulsions and structured systems; studies show it can be emulsified with alternative proteins (e.g., Arthrospira protein extracts) and used in processing contexts, which may enable new food formats (not a direct health outcome).

4. Does it have any downsides or side effects?

• Gastrointestinal side effects (noted in epilepsy MCTKD): The MCT ketogenic diet literature notes diarrhea, vomiting, bloating, and cramps as associated GI side effects, which has contributed to underutilization. The author notes that careful clinical management can optimize tolerance even at high MCT percentages (>70% of calories), but side effects remain a key limitation.

• May be a poor solvent/vehicle for some lipophilic drugs compared with surfactant micelles: In the guinea pig airway inflammation model, cannabinoids in MCT oil were not effective, whereas a Cremophor EL micellar formulation was. This implies that for certain compounds, MCT oil may lead to lower bioavailability than surfactant-based systems (a “downside” in drug delivery contexts).

• Uncertainty about long-term use and population-specific guidance: The review abstract explicitly notes limited information on daily requirements, impacts in specific population groups, and effects of long-term consumption. This is a practical safety/efficacy limitation: absence of strong long-term data is not proof of harm, but it constrains confident recommendations.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic findings (e.g., differential response or adverse effects by genotype such as APOE status in Alzheimer’s disease, or fatty-acid oxidation gene variants). Therefore:

• No genotype-specific benefits or harms can be concluded from these studies.

• Given the mixed cognitive outcomes in MCFA/MCT studies in MCI/AD, future work commonly examines whether factors like APOE genotype modify response, but such results are not included in the text provided.

Research Summary on Medium Chain Triglycerides (MCTs)

The absorption of medium chain triglycerides (MCTs), particularly lauric and octanoic acids, through the lymphatic system has been shown to be notable, although it varies between different MCTs. MCTs are not preferentially absorbed directly into the portal vein, suggesting involvement of the lymphatic system to some extent.

Medical and Nutritional Uses of MCTs

MCTs have been utilized in treating malabsorption and hyperlipidemia. They have applications in medical nutrition therapy, including hyperalimentation, carnitine deficiency, epilepsy, and obesity. The metabolism of MCTs occurs in the liver and other tissues.

MCTs and Dietary Fat Absorption

Understanding dietary fat absorption is crucial in the context of the obesity epidemic. MCTs affect the secretion of digestive hormones like cholecystokinin (CCK) and influence human gastric motility. They also impact the secretion of pancreatic enzymes and gallbladder function differently from long-chain triglycerides (LCTs).

Impact of MCTs on Fatty Acid Composition

Different dietary fats, including MCTs, LCTs, and structured lipids, directly influence the fatty acid composition of the intestine and the absorption process in the lymphatic system and portal vein.

Research Findings on MCT Supplementation

• MCT consumption may lead to a reduction in food intake and aid in weight control.
• When ingested with beta-carotene, MCTs decrease its bioavailability.
• MCTs, as part of a high-fat diet, can lead to significant incorporation of medium-chain fatty acids into chylomicron triglycerides.
• MCTs may not stimulate the secretion of pancreatic enzymes or gallbladder contraction like LCTs do.

Considerations for MCT Use in Treatment

Further studies are needed to understand the implications of MCT supplementation in the treatment of conditions such as chylous leaks and to explore the factors influencing the absorption of fatty acids of different chain lengths in both healthy and pathological states.

Conclusions

The reviewed research suggests that while MCTs have several health and nutritional benefits, their absorption patterns and effects on the body's metabolism are complex and may differ from long-chain fatty acids. This warrants additional research to fully comprehend their role in medical and nutritional contexts.

References:

1. Lymphatic absorption of glucose and fatty acids as determined by direct measurement
2. Determination of the route of medium-chain and long-chain fatty acid absorption by direct measurement in the rat
3. Medium-chain triglycerides: an update
4. The metabolism of structured triacylglycerols
5. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons
6. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility
7. The effect of equicaloric medium-chain and long-chain triglycerides on pancreas enzyme secretion
8. Effects of medium-chain triglycerides, long-chain triglycerides, or 2-monododecanoin on fatty acid composition in the portal vein, intestinal lymph, and systemic circulation in rats
9. Relative rates of metabolism MCT, LCT and ethanol in man
10. Chylomicron beta-carotene and retinyl palmitate responses are dramatically diminished when men ingest beta-carotene with medium-chain rather than long-chain triglycerides
11. Medium-chain fatty acids: evidence for incorporation into chylomicron triglycerides in humans
12. Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects
13. Effect of the fatty acid composition of ingested fats on rat liver intermediary metabolism
14. Oxaloacetate deficiency in MCT-induced ketogenesis
15. Regulation of hepatic fatty acid oxidation and ketone body production
16. Relation of ketosis to metabolic changes induced by acute medium-chain triglyceride feeding in rats
17. Ketogenic response to medium-chain triglyceride load in the rat
18. The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis
19. Uptake of valproic acid into rat brain is mediated by a medium-chain fatty acid transporter
20. Seizure control by decanoic acid through direct AMPA receptor inhibition
21. Substrate oxidation and control of food intake in men after a fat-substitute meal compared with meals supplemented with an isoenergetic load of carbohydrate, long-chain triacylglycerols, or medium-chain triacylglycerols
22. Food intake in dieters and nondieters after a liquid meal containing medium-chain triglycerides
23. Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men
24. Influence of medium-chain and long-chain triacylglycerols on the control of food intake in men
25. Covert manipulation of the ratio of medium- to long-chain triglycerides in isoenergetically dense diets: effect on food intake in ad libitum feeding men
26. Value of VLCD supplementation with medium chain triglycerides
27. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects
28. Ketogenic diet and other dietary treatments for epilepsy
29. Neurobiochemical mechanisms of a ketogenic diet in refractory epilepsy
30. Mechanisms of Ketogenic Diet Action
31. Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy
32. Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet
33. Medium-chain triglycerides as a therapy for intractable childhood epilepsy
34. Ketonemia and seizures: metabolic and anticonvulsant effects of two ketogenic diets in childhood epilepsy
35. Medium-chain triglyceride (MCT) diet in intractable seizure disorders
36. The medium chain triglyceride diet and intractable epilepsy
37. Ketogenic diets in the treatment of epilepsy: short-term clinical effects
38. Metabolic effects of three ketogenic diets in the treatment of severe epilepsy
39. Medium-chain triglyceride (MCT) ketogenic therapy
40. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets
41. Growth of children on classical and medium-chain triglyceride ketogenic diets
42. A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treatment of childhood epilepsy
43. Marked Seizure Reduction after MCT Supplementation
44. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults
45. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial
46. Pilot feasibility and safety study examining the effect of medium chain triglyceride supplementation in subjects with mild cognitive impairment: A randomized controlled trial
47. Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's Disease
48. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women
49. Mechanisms mediating lipoprotein responses to diets with medium-chain triglyceride and lauric acid
50. Effects of medium chain fatty acids (MCFA), myristic acid, and oleic acid on serum lipoproteins in healthy subjects
51. Plasma lipids and lipoproteins during 6 d of maintenance feeding with long-chain, medium-chain, and mixed-chain triglycerides
52. Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides
53. Effect of a saturated medium-chain triglyceride on serum-lipids in man
54. Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil
55. Dietary medium-chain triglyceride supplementation has no effect on apolipoprotein B-48 and apolipoprotein B-100 kinetics in insulin-resistant men
56. Dietary medium chain fatty acid supplementation leads to reduced VLDL lipolysis and uptake rates in comparison to linoleic acid supplementation
57. Effect of high fat weanling diets containing either medium-chain triglycerides or long-chain triglycerides on the development of obesity in the Zucker rat
58. Effect of dietary medium- and long-chain triacylglycerols (MLCT) on accumulation of body fat in healthy humans
59. Consumption of medium- and long-chain triacylglycerols decreases body fat and blood triglyceride in Chinese hypertriglyceridemic subjects
60. [Medium- and long-chain fatty acid triacylglycerol reduce body fat and serum triglyceride in overweight and hypertriglyceridemic subjects]
61. A good response to oil with medium- and long-chain fatty acids in body fat and blood lipid profiles of male hypertriglyceridemic subjects
62. Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture
63. Medium- and long-chain triacylglycerols reduce body fat and blood triacylglycerols in hypertriacylglycerolemic, overweight but not obese, Chinese individuals
64. Dietary medium-chain triacylglycerol prevents the postprandial rise of plasma triacylglycerols but induces hypercholesterolemia in primary hypertriglyceridemic subjects
65. Comparison of the effects of medium-chain triacylglycerols, palm oil, and high oleic acid sunflower oil on plasma triacylglycerol fatty acids and lipid and lipoprotein concentrations in humans
66. HYPERGLYCERIDEMIA RESULTING FROM INTAKE OF MEDIUM CHAIN TRIGLYCERIDES
67. Dietary substitution of medium-chain triglycerides improves insulin-mediated glucose metabolism in NIDDM subjects
68. A Diet Rich in Medium-Chain Fatty Acids Improves Systolic Function and Alters the Lipidomic Profile in Patients With Type 2 Diabetes: A Pilot Study
69. Medium-chain triacylglycerols may not raise cholesterol
70. Insulin and ketone responses to ingestion of medium and long-chain triglycerides in man
71. Effects of a single oral load of medium-chain triglyceride on serum lipid and insulin levels in man
72. Dietary substitution of medium chain triglycerides in subjects with non-insulin-dependent diabetes mellitus in an ambulatory setting: impact on glycemic control and insulin-mediated glucose metabolism
73. Effects of feeding medium-chain triacylglycerols on maternal lipid metabolism and pup growth in lactating rats
74. Difference in hepatic metabolism of long- and medium-chain fatty acids: the role of fatty acid chain length in the production of the alcoholic fatty liver
75. Medium-chain-triglyceride lipid emulsion: metabolism and tissue distribution
76. Diagnosis and differentiation of fat malabsorption in children using 13C-labeled lipids: trioctanoin, triolein, and palmitic acid breath tests
77. Medium- and long-chain triglycerides labeled with 13C: a comparison of oxidation after oral or parenteral administration in humans
78. 13C abundances of nutrients and the effect of variations in 13C isotopic abundances of test meals formulated for 13CO2 breath tests
79. Endogenous fat oxidation during medium chain versus long chain triglyceride feeding in healthy women
80. Influence of human obesity on the metabolic fate of dietary long- and medium-chain triacylglycerols
81. Carnitine Palmitoyltransferase 1A Deficiency
82. Overfeeding with medium-chain triglyceride diet results in diminished deposition of fat
83. Differential effects of high-fat diets varying in fatty acid composition on the efficiency of lean and fat tissue deposition during weight recovery after low food intake
84. Metabolic effects induced by long-term feeding of medium-chain triglycerides in the rat
85. Effect of medium chain triglyceride on lipogenesis and body fat in the rat
86. Components of total energy expenditure in healthy young women are not affected after 14 days of feeding with medium-versus long-chain triglycerides
87. Value of VLCD supplementation with medium chain triglycerides
88. Structured medium and long chain triglycerides show short-term increases in fat oxidation, but no changes in adiposity in men
89. Effects of dietary coconut oil on the biochemical and anthropometric profiles of women presenting abdominal obesity
90. Effect of dietary medium- and long-chain triacylglycerols (MLCT) on accumulation of body fat in healthy humans
91. Dietary medium-chain triacylglycerols suppress accumulation of body fat in a double-blind, controlled trial in healthy men and women
92. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects
93. Medium-chain triglycerides are advantageous in promoting weight loss although not beneficial to exercise performance
94. Strategies to enhance fat utilisation during exercise
95. Preexercise medium-chain triglyceride ingestion does not alter muscle glycogen use during exercise
96. Chronic medium-chain triacylglycerol consumption and endurance performance in trained runners
97. The effects of medium-chain triacylglycerol and carbohydrate ingestion on ultra-endurance exercise performance
98. Effect of carbohydrate or carbohydrate plus medium-chain triglyceride ingestion on cycling time trial performance
99. The effect of medium-chain triglyceride on 47 calcium absorption in patients with primary biliary cirrhosis
100. Effect of medium chain triglyceride on fecal calcium losses in pancreatic insufficiency
101. The effects of medium-chain triglycerides in the short bowel syndrome. Increased glucose and water transport
102. Review of the toxicologic properties of medium-chain triglycerides
103. A simple practice guide for dose conversion between animals and human
104. Effect of different oils and ultrasound emulsification conditions on the physicochemical properties of emulsions stabilized by soy protein isolate.
     Ahmed Taha, Tan Hu, Zhuo Zhang, Amr M Bakry, Ibrahim Khalifa, Siyi Pan, Hao Hu (2018) - Ultrasonics sonochemistry
105. Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants.
     Kristina Wendel, Marlen Fossan Aas, Gunnthorunn Gunnarsdottir, Madelaine Eloranta Rossholt, Marianne Bratlie, Tone Nordvik, Erlend Christoffer Sommer Landsend, Drude Fugelseth, Magnus Domellöf, Are Hugo Pripp, Tom Stiris, Sissel Jennifer Moltu (2023) - Clinical nutrition (Edinburgh, Scotland)
106. 3D printed MCT oleogel as a co-delivery carrier for curcumin and resveratrol.
     M Kavimughil, M Maria Leena, J A Moses, C Anandharamakrishnan (2022) - Biomaterials
107. Medium chain triglycerides (MCT): State-of-the-art on chemistry, synthesis, health benefits and applications in food industry.
     Shubham Nimbkar, M Maria Leena, J A Moses, C Anandharamakrishnan (2022) - Comprehensive reviews in food science and food safety
108. Effect of Oil Content and Oil Addition Point on the Extrusion Processing of Wheat Gluten-Based Meat Analogues.
     Christina Kendler, Arvid Duchardt, Heike P Karbstein, M Azad Emin (2021) - Foods (Basel, Switzerland)
109. Impact of oil type and WPI/Tween 80 ratio at the oil-water interface: Adsorption, interfacial rheology and emulsion features.
     Andresa Gomes, Ana Letícia Rodrigues Costa, Rosiane Lopes Cunha (2018) - Colloids and surfaces. B, Biointerfaces
110. The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination.
     Carmen Lorena Robaina Cabrera, Sandra Keir-Rudman, Nick Horniman, Nick Clarkson, Clive Page (2021) - Pulmonary pharmacology & therapeutics
111. Pulmonary Toxicity and the Pathophysiology of Electronic Cigarette, or Vaping Product, Use Associated Lung Injury.
     Hitendra S Chand, Thivanka Muthumalage, Wasim Maziak, Irfan Rahman (2019) - Frontiers in pharmacology
112. Effect of Arthrospira platensis microalgae protein purification on emulsification mechanism and efficiency.
     Lukas Böcker, Pascal Bertsch, David Wenner, Stephanie Teixeira, Jotam Bergfreund, Severin Eder, Peter Fischer, Alexander Mathys (2021) - Journal of colloid and interface science
113. Hemp in Veterinary Medicine: From Feed to Drug.
     Giorgia Della Rocca, Alessandra Di Salvo (2020) - Frontiers in veterinary science
114. Interactions of β-carotene with WPI/Tween 80 mixture and oil phase: Effect on the behavior of O/W emulsions during in vitro digestion.
     Andresa Gomes, Ana Letícia Rodrigues Costa, Dayane Dias Cardoso, Grazielle Náthia-Neves, M Angela A Meireles, Rosiane Lopes Cunha (2021) - Food chemistry
115. Efficacy of a Therapeutic Diet on Dogs With Signs of Cognitive Dysfunction Syndrome (CDS): A Prospective Double Blinded Placebo Controlled Clinical Study.
     Yuanlong Pan, Gary Landsberg, Isabelle Mougeot, Stephanie Kelly, Hui Xu, Sandeep Bhatnagar, Cari L Gardner, Norton W Milgram (2018) - Frontiers in nutrition
116. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders.
     J Vockley, J Charrow, J Ganesh, M Eswara, G A Diaz, E McCracken, R Conway, G M Enns, J Starr, R Wang, J E Abdenur, J Sanchez-de-Toledo, D L Marsden (2016) - Molecular genetics and metabolism
117. Effect of enzymolysis and glycosylation on the curcumin nanoemulsions stabilized by β-conglycinin: Formation, stability and in vitro digestion.
     Chang Liu, Zhongjiang Wang, Hua Jin, Xiaoyu Wang, Yu Gao, Qingshan Zhao, Chunhong Liu, Jing Xu (2020) - International journal of biological macromolecules
118. Development of Chrysin Loaded Oil-in-Water Nanoemulsion for Improving Bioaccessibility.
     Pisamai Ting, Wanwisa Srinuanchai, Uthaiwan Suttisansanee, Siriporn Tuntipopipat, Somsri Charoenkiatkul, Kemika Praengam, Boonrat Chantong, Piya Temviriyanukul, Onanong Nuchuchua (2021) - Foods (Basel, Switzerland)
119. Revisiting the metabolism and physiological functions of caprylic acid (C8:0) with special focus on ghrelin octanoylation.
     Fanny Lemarié, Erwan Beauchamp, Philippe Legrand, Vincent Rioux (2016) - Biochimie
120. Characterization of physical properties and electronic sensory analyses of citrus oil-based nanoemulsions.
     Ying Yang, Chengying Zhao, Guifang Tian, Chang Lu, Chengxiu Li, Yuming Bao, Zhonghai Tang, David Julian McClements, Hang Xiao, Jinkai Zheng (2018) - Food research international (Ottawa, Ont.)
121. Efficacy of supplemental MCT oil on seizure reduction of adult drug-resistant epilepsy - a single-center open-label pilot study.
     Emmaline Rasmussen, Vimal Patel, Samuel Tideman, Robert Frech, Roberta Frigerio, Jaishree Narayanan (2023) - Nutritional neuroscience

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!